Search
Abivax SA
ABVXAdd to Watchlist
87.580USD
-2.620-2.90%
Close 11-13 16:00（ET）
7.64BMarket Cap
0.00P/E TTM
About Abivax SA Company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA Profile
Ticker SymbolABVX
Company nameAbivax SA
IPO dateJun 26, 2015
CEOde Garidel (Marc)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address7-11 Boulevard Haussmann
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75009
Phone33153830963
Websitehttps://www.abivax.com/
Ticker SymbolABVX
IPO dateJun 26, 2015
CEOde Garidel (Marc)
Company Executives of Abivax SA
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Ms. Jennifer Fine
Ms. Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Mr. Kim Kelly
Mr. Kim Kelly
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Keith Fournier, Ph.D.
Dr. Keith Fournier, Ph.D.
Senior Vice President - Global Regulatory Affair
Senior Vice President - Global Regulatory Affair
--
--
Dr. Maurus de la Rosa, Ph.D.
Dr. Maurus de la Rosa, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
FAQs
Who are the top five shareholders of Abivax SA?
The top five shareholders of Abivax SA are: Mr. Pierre Courteille
How many institutions hold shares of Abivax SA (ABVX)?
As of 2026Q1, 353 institutions hold shares of Abivax SA, with a combined market value of approximately 61.40M, accounting for 78.18% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -289711.00.